testosterone
Print| Trade Name(s): Depo-testosterone; Jatenzo; Kyzatrex; Natesto; Testopel; Tlando; Xyosted; Fortesta; Testim; Testosterone; Vogelxo | |
| Group 2: Non-Antineoplastic Hazardous | AHFS Class: Androgens; Antigonadotropins |
| Formweb: testosterone | |
| Info Links: Chemotherapy Extravasation Policy | |
| Activity | Glove | Gown | Eye | Mask (N95/PAPR) | CSTD |
| Administration |  |
If splashing possible |
If inhalation possible | ||
| Waste/Disposal of drug | |
If splashing possible |
If inhalation possible |
Nursing Non-Antineoplastic or Reproductive Risk Drug PPE and Work Practices (Link to a file uploaded to Rhazdrugs or to a file on your intranet, or a shared drive.)
| Activity | Glove | Gown | Eye | Mask (N95/PAPR) |
| Administration |
single glove if only applying from intact form (i.e., patch, device) |  |
If splashing possible |
If inhalation possible |
| Waste/Disposal of drug |  | |  If splashing possible |  If inhalation possible |
Handling of bodily fluids and/or contaminated materials
| Drug Form | Glove | Gown | Eye | Mask (N95/PAPR) | Shoe |
| Intact tablet or capsule from UD package | | ||||
| Non-intact, repackaged tablet or capsule | | ||||
| Oral liquid drug or feeding tube | | ||||
| Topical drug | | If splashing possible | If splashing possible | If inhalation possible | |
| Powder, solution for inhalation | | | | | |
| Vial; ampule; pre-filled syringe | | If splashing possible | If inhalation possible | ||
| Intravenous solutions | | If splashing possible | If inhalation possible | ||
| Irrigation solutions | | If splashing possible | If inhalation possible |
| Form | Receipt Packaging | Environment | Glove | Storage | Labeling |
| All Forms | No additional action | No additional action | | May be stored within normal inventory, neutral or positive | Cautionary Labeling |
Pharmacy Non-Antineoplastic or Reproductive Risk Drugs PPE and Work Practices
| Glove | Gown | Eye | Resp | Shoe | Head | Hood/Cabinet | CSTD |
(outer layer should be sterile) | |  |  |  |
LAFW |
Pharmacy Non-Antineoplastic or Reproductive Risk Drugs PPE and Work Practices
| Glove | Gown | Eye | Mask (N95/PAPR) | Shoe | Hood/Cabinet | CSTD |
|
*NO Manipulation
| Form | Prep Instructions | Pneumatic Tube |
| Intact tablet/capsule from UD package | Sealed plastic bag, single pair of gloves, cautionary labeling |  |
| Non-intact, repackaged tablet or capsule | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Oral liquid drug or feeding tube | Sealed plastic bag, single pair of gloves, cautionary labeling |  |
| Topical drug | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Powder, solution for inhalation | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Vial; ampule; pre-filled syringe | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Intravenous solution | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Irrigation solution | Sealed plastic bag, single pair of gloves, cautionary labeling | |
| Dosage Form | Risk of Exposure | Packaging | Pharmacy Manipulation | Nurse Manipulation |
| Injectable | May occur when withdrawing from vial and administration | Vial | Dispense in intact packaging or admixture in LAFW | If preparing in patient care area, utilize PPE as stated in handling guide. |
| Topical | May occur when administering | Topical emulsion in single dose packaging | Dispense in intact packaging | None |
| Implant | May occur when implanting | Implant in single dose packaging | Dispense intact packaging | If preparing in patient care area, utilize PPE as stated in handling guide. |
| |  | | |  | |  |
| Chemotherapy rated/tested (tested to ASTM D6978-05 (2013), Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs) | Disposable
| Should be worn in situations where eye, mouth, or nasal splashing is possible (i.e., during a bladder instillation of a hazardous drug) | Goggles protect the eyes, but not the face, against spraying. | Certified N95 | Powered air purifying respirator | required for compounding sterile and nonsterile hazardous drugs | required for compounding sterile and nonsterile hazardous drugs |
| Powder-free | Shown to resist permeation by hazardous drugs
| N95 offers no protection against gases and vapors. | For events such as large spills when an IV bag breaks or a line disconnects and leaks, or where there is known or suspected airborne exposure to vapors or gases | Double booties required for HD preparation areas, top layer is doffed before exiting the HD buffer room. | |||
| Inspect for visible defects | Must close in the back (no open front) | Surgical masks do NOT provide respiratory protection from drug exposure | Hazardous drugs with potential to vaporize at room temperature: • Carmustine • Cisplatin •Cyclophosphamide • Etoposide • 5-Fluorouracil • lfosfamide • Thiotepa | ||||
| Double gloving is recommended for all activities involving hazardous drugs except for handling intact, unit-dose oral agents, when one pair of chemotherapy-tested gloves is acceptable | Long sleeves with closed cuffs that are elastic or knit | ||||||
| When wearing double gloves, tuck the cuff of the inner glove under the gown sleeve and the cuff of the outer glove over the gown sleeve. | No seams or closures that could allow hazardous drugs to pass through | ||||||
| During medication manipulation/compounding the outer layer should be sterile | In preparation areas gowns should be changed every 2-3 hours or immediately after a spill or splash | ||||||
Change gloves every 30 minutes unless permeation testing has noted shorter time limits
| Gowns worn in hazardous drug handling areas must NOT be worn to other areas |
Sequence for Donning & Doffing PPE
References: Oncology Nursing Society, NIOSH
Testosterone mediates its effects by activating androgen receptors directly or as DHT, or being converted to estradiol which acts as an endogenous lignad on estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT displays an androgenic potency that is about 2.5 times higher than to that of free T. Upon formation, the T-receptor or DHT-receptor complex undergoes a structural change that allows translocation of the complex into the cell nucleus and direct binding to the specific nucleotide sequences of the chromosomal DNA as a transcription factor. These specific nucleotide sequences are also called hormone response elements (HREs) that, when activated, promote transcriptional activity of certain genes responsible for the androgen effects.
Reference: Drug Bank
- Harmful if swallowed
- May cause cancer
- Suspected of causing cancer
- May damage fertility or the unborn child
- Suspected of damaging fertility or the unborn child
- May cause harm to breast-fed children
- Causes damage to organs through prolonged or repeated exposure
- Environmental hazards
Reference: PubChem
CSA SCH: C-III
